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ABSTRACT
The aim of the present study was to analyse the
molecular mechanisms involved in the Interleukin-6
(IL-6) silencing in pancreatic adenocarcinoma cell
lines. Our results demonstrate that TNF-a, a major
IL-6 inducer, is able to induce IL-6 only in three out
of six cell lines examined. 5-aza-20-deoxycytidine
(DAC), but not trichostatin A (TSA), activates the
expression of IL-6 in all cell lines, indicating that
DNA methylation, but not histone deacetylation,
plays an essential role in IL-6 silencing. Indeed, the
IL-6 upstream region shows a methylation status
that correlates with IL-6 expression and binds
MeCP2 and H3meK9 only in the non-expressing
cell lines. Our results suggest that critical methy-
lations located from positions –666 to –426 relative
to the transcription start site of IL-6 may act as
binding sites for MeCP2.
INTRODUCTION
Interleukin-6 (IL-6) is a cytokine produced constitutively
and/or under speciﬁc stimuli by almost all nucleated cells
(1). Its biological role includes a wide range of activities,
such as the regulation of the immune response, the acute-
phase reaction, cell proliferation and diﬀerentiation,
apoptosis and cell traﬃcking (1,2). All these activities
may have a direct correlation to the pathogenesis of
several diseases, including various types of cancers (3–5).
Pancreatic adenocarcinoma is a very aggressive cancer,
characterized by a high frequency of gene mutations
(TP53, K-RAS, P16 and DPC4) (6) and alterations in
the expression of secondary messengers involved in
cancer pathogenesis (1). In pancreatic cancer, IL-6
deregulation has been associated with carcinogenesis, cell
proliferation, angiogenesis, alteration in cell adhesion
molecules and chemotaxis, and reduction of sensitivity
to apoptosis (1,7,8).
Transcriptional activation of IL-6 has been extensively
studied (9–12), whereas the mechanisms involved in its
repression remain largely unclariﬁed (13–19).
Epigenetic events, such as DNA methylation and
histone modiﬁcations, play critical roles in gene
silencing, which is a key event in both carcinogenesis
and drug resistance (20,21). DNA methylation leads to
transcriptional repression either by directly interfering
with the binding of transcription factors or by the
involvement of proteins that speciﬁcally recognize
methylated CpGs (mCpGs) (22), the prototype of
which is the methyl-CpG-binding protein 2 (MeCP2).
Two independent, not mutually exclusive, mechanisms
have been claimed for MeCP2 activities (23). In the
enzymatic model, MeCP2 speciﬁcally targets mCpGs
and determines repressive heterochromatin by interact-
ing with the co-repressor mSin3A, which is part of a
large complex containing histone deacetylases (HDACs)
(24,25). MeCP2 can also recruit histone methyltrans-
ferase that methylates local H3 lysine 9 strengthening
the repressive state (26). In this model, repression may
be partially or totally relieved by the HDAC inhibitor
trichostatin A (TSA). The structural model, which
is not aﬀected by HDAC inhibitors, postulates the
ability of MeCP2 to repress gene transcription by
mechanisms of chromatin condensation independent of
histone acetylation (23).
In the present work, we have studied the molecular
mechanisms leading to IL-6 repression in three non-
expressing and three IL-6-expressing pancreatic
adenocarcinoma cell lines. We demonstrate that in all
cell lines the DNA methyltransferase inhibitor 5-aza-20-
deoxycytidine (DAC) induces IL-6 transcription, while
the HDAC inhibitor TSA does not signiﬁcantly modify
IL-6 expression. Furthermore, we report that the IL-6
upstream region shows a methylation status that
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H3meK9 only in the non-expressing cell lines.
MATERIALS AND METHODS
Reagents
TSA and DAC were purchased from Sigma (Sigma–
Aldrich), solubilized in DMSO and stored at  80 C
until use. TNF-a (PeproTech, Calbiochem) was
solubilized in PBS/1% BSA. Sodium bisulphite was
obtained from Sigma–Aldrich.
Cell lines
Six human pancreatic adenocarcinoma cell lines, PaCa44,
CFPAC1, PT45P1, PC, HPAFII and Panc1 [Moore et al.
(6) for genetic characterization and primary tissue source],
were grown in RPMI 1640 supplemented with 10% FBS
and 50mg/ml gentamicin sulphate (BioWhittaker), and
were incubated at 37 C with 5% CO2. All cell lines were
routinely screened for mycoplasma contamination by
PCR analysis.
RNA extraction and northern blot analysis
Total RNA from 5 10
6cells was extracted by TRIzol
Reagent (Invitrogen) according to the manufacturer’s
instructions. Cells were treated with TNF-a (5ng/ml) for
1h. Ten micrograms of denaturated RNA was separated
by electrophoresis in 1% agarose gel containing 5% form-
aldehyde and 20mM 3-[N-morpholino]propanesulphonic
acid (MOPS) and was transferred onto nylon membranes
(Hybond-N, Amersham-Pharmacia Biotech.) in 10  SSC.
The membranes were hybridized overnight at 65 C with
a
32P-labelled IL-6 cDNA probe (DECAprimeII kit,
Ambion) in a solution containing 7% SDS, 1% BSA,
1mM EDTA and 50% NaH2PO4. Filters were cold
washed twice with a solution containing 5% SDS, 0.5%
BSA, 1mM EDTA and 4% NaH2PO4, then twice at
65 C with a pre-warmed solution containing 1% SDS,
1mM EDTA and 4% NaH2PO4. Speciﬁc mRNAs
were detected and quantiﬁed by scanning the ﬁlters in
the PhosphorImager (Molecular Dynamics) using
ImageQuant software (ACHS).
IL-6 enzyme-linked immunosorbent assay
Cells were seeded in 96-well microtiter plates (4 10
3cells/
well) and treated for 24h with TNF-a (5ng/ml). Culture
supernatants were assayed for IL-6 production by
PREDICTA
TM kit (Genzyme diagnostic) according to
the manufacturer’s instructions.
Nuclear extracts and electrophoretic mobility shift assay
Nuclear extracts were prepared according to Osborn et al.
(27) from 5 10
6cells treated with TNF-a (5ng/ml) for
30min and/or DAC (2.5mM) for 72h and/or TSA
(300nM) for the last 8h. Protein concentration was
measured by the Coomassie Protein Assay Reagent
(Pierce), using BSA as a standard. Binding reactions
were carried out using 10mg of nuclear protein
extracts in a binding buﬀer containing 20mM Hepes
(pH 7.5), 50mM KCl, 0.5mM DTT, 0.1mM EDTA,
10% glycerol and 2mg Poly(dI-dC) (Amersham).
Radiolabelled probe (0.02pmol; sp.act 3 10
6cpm/
pmol) was added last to each reaction mix, and samples
were incubated at room temperature for 30 minutes.
In competition assays, a 200-fold molar excess of cold
double-stranded oligonucleotides was added to the
reaction mix. Samples were run on 5% (30:1.2) native
polyacrylamide gel in 0.5  TBE, dried, detected and
quantiﬁed by scanning the ﬁlters in the PhosphorImager
(Molecular Dynamics) using ImageQuant software
(ACHS). The oligonucleotide sequences used were 50-AA
TGTGGGATTTTCCCATG-30 for IL-6-NF-kB and 50-C
TCAACCCCCAATAAATAT-30 for IL-6-C/EBP. The
formation of speciﬁc complexes was previously established
by using speciﬁc antibodies.
Plasmid constructs and transient transfections
The reporter constructs p4xNF-kB-LUC and p4xC/EBP-
LUC were obtained by cloning four tandem repeats of
NF-kB or C/EBP binding sites of the IL-6 promoter
into the pGL Promoter vector (Promega). The pIL-
6( 592) construct was obtained by inserting the MscI/
XhoI fragment of the human IL-6 promoter into the
pGL Basic vector (Promega). All plasmids were ampliﬁed
in dam
  bacterial strains. 2.5 10
5 cells/well were seeded
in 6-well plates. Twenty-four hours later, transfections
were carried out with FuGENE 6 Transfection Reagent
(Roche) keeping a transfection reagent:DNA ratio of 3:2.
TNF-a (5ng/ml) stimulation was carried out 18h later.
Twenty-four hours after transfection, reporter gene
activity was determined by Luciferase Assay System
(Promega) according to the manufacturer’s instructions.
When DAC treatment was performed, cells were seeded
in a six-well plate at a density of 1.5 10
5cells/well and
DAC (2.5mM) was added after 24h. Forty-eight hours
later, the pIL-6( 592) vector was transfected with
FuGENE 6 Transfection Reagent. Twenty-four hours
after transfection, reporter gene activity was determined
by Luciferase Assay System.
In each transfection, 0.2mg of pSV gal was added, and
the luciferase activity was normalized with respect to the
 -galactosidase activity.
RT–PCR
Total RNA was extracted as described above. One
microgram of total RNA was reverse-transcribed by
First Strand cDNA Synthesis (Invitrogen) in a ﬁnal
volume of 20ml. One microlitre of cDNA was used for
PCR ampliﬁcation. The sequences of the primers were as
follows: IL6 forward 50-CTTCTCCACAAGCGCCTTC
G-30; IL6 reverse 50-TACTCTTGTTACATGTCTCC-30;
 -ACTIN forward 50-ACCAACTGGGACGACATGGA
GAA-30;  -ACTIN reverse 50-TGGTGGTGAAGCTGT
AGCC-30. PCR conditions included 25–40 cycles
(depending on cell lines and genes) at 94 C for 1min,
58 C for 1min and 72 C for 30s, and a ﬁnal extension
at 72 C for 4min.  -ACTIN was used as an internal
standard to evaluate the relative expression levels of
6682 Nucleic Acids Research, 2009,Vol.37, No. 20IL-6. PCR products were separated by electrophoresis in
1.5% agarose gel and stained with ethidium bromide.
DNA methylation analysis
The DNA methylation status was analysed by bisulphite
genomic sequencing (BGS). Genomic DNA was extracted
from cultured cells by Wizard Genomic DNA Puriﬁcation
Kit (Promega) and used for bisulphite treatment per-
formed with EZ DNA Methylation-Gold kit (Zymo
Research, Orange, California) according to the manufac-
turer’s instructions.
Fifty nanograms of each modiﬁed DNA was ampliﬁed
by PCR from  1150 to +50 with respect to the IL-6
transcriptional start site.
PCR products were separated by electrophoresis in
1.5% agarose gel stained with ethidium bromide,
excised, cleaned by Qiagen Gel Extraction Kit (Qiagen)
and used for pyrosequencing analysis. The pyrose-
quencing service was oﬀered by EpigenDx Inc
(Worcester, Massachusetts). The assay design package
including primer sequences and PCR conditions is avail-
able on request.
Chromatin immunoprecipitation assays.
Chromatin immunoprecipitation (ChIP) assays were
performed using the EpiQuik TM Chromatin
Immunoprecipitation Kit (Epigentek) according to the
manufacturer’s instructions. Brieﬂy, DMSO (control),
TNF-a-, DAC- or TNF-a/DAC-treated cells were ﬁxed
using 1% formaldehyde at room temperature for 10min.
Cells were washed twice in ice-cold PBS, resuspended in
SDS lysis buﬀer and sonicated until crosslinked chromatin
was sheared to an average DNA fragment molecular
length of 300–500bp. Five per cent of the sonicated
lysate was used to quantify the total amount of DNA
present in diﬀerent samples before immunoprecipitation
(inputs). Chromatin preparations were immunopre-
cipitated using antibodies anti-RNA polymerase II
(PolII), anti-histone H4 acetylated (H4Ac, Upstate
Biotechnology), anti–dimethylhistone H3 (Lys9)
(H3meK9, Upstate Biotechnology), anti-methyl-CpG-
binding protein 2 (MeCP2, Abcam) and a non-speciﬁc
antibody (IgG). Non-immunoprecipitated samples
(NoAb) were used as negative controls. Precipitated
complexes were bound to Protein A Agarose, washed
and then eluted in 1% SDS/0.1M NaHCO3.
Crosslinking between DNA and proteins was reversed
by heating the samples at 65 C for 15min, followed by
Proteinase K digestion at 65 C for 1.5h. After cleaning on
spin columns, DNA was eluted in 20mlo f1 0 mM Tris–
EDTA. Four microlitres of ChIP-DNA was analysed
using Brilliant SYBR Green QPCR Master Mix
(Stratagene, La Jolla, CA, USA) and the Stratagene
Mx3005P
TM QPCR System. qPCR was performed in trip-
licate with primers for IL-6,  -ACTIN and the human
chromosome 16 centromere region (16CEN).
The sequences of the primers used for  -ACTIN and
16CEN were:  -ACTIN For 50-CTGCGCATAGCAGA
CATACAA-30 and  -ACTIN Rev 50-CTGGGCTTGAG
AGGTAGAGTG-30; 16CEN For 50-GTCTCTTTCTTG
TTTTTAAGCTGGG-30 and 16CEN Rev 50-TGAGCTC
ATTGAGACATTTGG-30. The sequences of the six
primer pairs used for IL-6 were: IL6-1 For 50-GGGCTT
CTGAACCAGCTTGA-30 and IL6-1 Rev 50-CAGGCAC
GGCTCTAGGCTC-30; IL6-2 For 50-AAGATGCCACA
AGGTCCTCCT-30 and IL6-2 Rev 50-CCACTTGGTTCA
GGGCAGA-30; IL6-3 For 50-CAGCAGCCAACCTCCT
CTAAGT-30 and IL6-3 Rev 50-CAAGGCGTCTCCAGG
TGG-30; IL6-4 For 50-AGGATGGCCAGGCAGTTC
TA-30 and IL6-4 Rev 50-AAGCCTGGGATTATGAAG
AAGGTA-30; IL6-5 For 50-TGCATGACTTCAGCTTT
ACTC-30 and IL6-5 Rev 50-GCAGAACCACTCTTCCT
TTAC-30; IL6-6 For 50-ACCGGGAACGAAAGAGAA
GC-30 and IL6-6 Rev 50-CTGGCAGTTCCAGGGCTA
AG-30. The following cycling conditions were used:
10min at 95 C, 40 cycles at 95 C for 30s, 65 C for
1min and 72 C for 30s. The average of cycle threshold
(CT) of each triplicate was analysed according to the
2
( Ct) method. For each cell line in each condition,
the result of the NoAb sample was subtracted from
those of the IgG, PolII, H4Ac, MeCP2 and H3MeK9
samples. The resulting data were divided by their corre-
sponding input DNA and ﬁnally plotted in a scale in
which the ﬁnal value of IgG was arbitrarily set to 1.
RESULTS
IL-6 expression in human pancreatic adenocarcinoma
cell lines
We analysed IL-6 expression in six human pancreatic
adenocarcinoma cell lines treated with TNF-a for 1h.
The presence of IL-6 mRNA was evaluated by northern
blot analysis. Figure 1A shows that mRNA IL-6 was con-
stitutively expressed in three of the cell lines examined
(PaCa44, CFPAC1 and PT45P1), and its level was
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Figure 1. IL-6 expression in human pancreatic adenocarcinoma cell
lines. (A) Cells were incubated in the absence or presence of TNF-a
for 1h. IL-6 induction was evaluated by northern blot analysis per-
formed as described in ‘Materials and Methods’ section. The expression
of  -ACTIN was used as an internal control. (B) Cells were incubated
in the absence or presence of TNF-a for 24h. Culture supernatants
from untreated and treated cells were assayed for IL-6 production as
described in ‘Materials and Methods’ section. The results are the
means±SE of three independent experiments.
Nucleic Acids Research, 2009,Vol.37, No. 20 6683increased in response to TNF-a. PC, HPAFII and Panc1
cells exhibited neither basal nor TNF-a-induced expres-
sion of IL-6 (Figure 1A). Consistent with the data of
gene expression, IL-6 was constitutively present in
PaCa44, CFPAC1 and PT45P1 cell lines and signiﬁcantly
increased after 24h of TNF-a treatment (Figure 1B). In
contrast, no IL-6 was detected in PC, HPAFII and Panc1
cells both in the absence and in the presence of TNF-a.
NF-iB and C/EBP DNA binding activity and their
functional role
To verify whether the absence of IL-6 production was
due to alterations in the transcriptional machinery,
we analysed the DNA binding activities of NF-kB and
C/EBP, the main transcription factors for IL-6 promoter
activation. Electrophoretic mobility shift assays (EMSAs)
performed with the IL-6-NF-kB oligonucleotide as a
probe showed the formation of speciﬁc and TNF-a-
inducible DNA-protein complexes in all cell lines
(Figure 2A: lanes 1, 2 and 9). EMSAs performed with
the IL-6-C/EBP oligonucleotide showed speciﬁc DNA-
protein complexes constitutive and non-inducible by
TNF-a (Figure 2B: lanes 1, 2 and 9). To determine
whether NF-kB and C/EBP were functionally active, we
carried out transfection assays with the reporter constructs
p4xNF-kB-LUC and p4xC/EBP-LUC, containing four
tandem repeats of the NF-kB or C/EBP binding sites of
the IL-6 promoter. In all cell lines, transfections with both
constructs produced a strong activation of the luciferase
gene following TNF-a induction (Figure 3), indicating
that either in non-expressing or in IL-6-expressing cell
lines TNF-a signalling and NF-kB and C/EBP trans-
criptional activities were similarly functional.
IL-6 regulation by DAC and/or TSA treatments
To study the involvement of epigenetic events in the IL-6
silencing in pancreatic cell lines, we examined IL-6 mRNA
expression by RT–PCR analyses following treatments
with DAC and/or TSA. Cells were treated with DAC
(2.5mM) for 72h and/or TSA (300nM) for the last 8h.
The time of TSA and DAC treatments was chosen on the
basis of our published results (28,29) and preliminary
experiments aimed to obtain the highest IL-6 mRNA
level and the most direct eﬀects of TSA and DAC.
Figure 4A shows that TSA did not signiﬁcantly modify
IL-6 expression, while DAC was able to induce IL-6
mRNA both in non-expressing and in IL-6-expressing
cell lines. The association TSA/DAC did not further
increase the level of DAC-induced IL-6 mRNA. It is
worth to note that a very diﬀerent number of PCR
cycles between the two groups of cell lines was necessary
to obtain a similar signal. Enzyme-linked immunosorbent
assay (ELISA) conﬁrmed that DAC, but not TSA, enables
PC, HPAFII and Panc1 cell lines to secrete detectable
levels of IL-6 (data not shown). To rule out the possibility
that DAC indirectly induces IL-6, we performed
transfection experiments with the unmethylated pIL-
6( 592) luciferase reporter plasmid in the absence or
presence of DAC. No signiﬁcant diﬀerence in luciferase
Figure 2. NF-kB and C/EBP DNA binding activity. Cells were treated
as described in ‘Materials and Methods’ section and cell extracts were
analysed by EMSAs using (A) the IL-6-NF-kBo r( B) the IL-6-C/EBP
oligonucleotides, as probes. Lanes: (1) uninduced; (2) TNF-a; (3) TSA;
(4) DAC; (5) TNF-a +TSA; (6) TNF-a+DAC; (7) TSA+DAC; (8)
TNF-a+TSA+DAC; (9) speciﬁc competitor. The arrows indicate
speciﬁc complexes.
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Figure 3. NF-kB and C/EBP transcriptional activity. Cell lines were
transfected with the plasmids p4xNF-kB-LUC and p4xC/EBP-LUC
obtained by cloning four tandem repeats of NF-kB or C/EBP
binding sites of the IL-6 promoter into the pGL Promoter vector.
TNF-a (5ng/ml) stimulation was carried out 18h later. Twenty-four
hours after transfection, luciferase gene activity was normalized with
respect to the b-galactosidase activity (RLU). The results are the
means±SE of three independent experiments.
6684 Nucleic Acids Research, 2009,Vol.37, No. 20activity between untreated and DAC-treated cells was
observed (Figure 4B).
Methylation pattern of the IL-6 upstream region
To verify whether DAC activates IL-6 expression by
epigenetic mechanisms, we examined by BGS (bisulphite
genomic sequencing) the methylation proﬁle of the IL-6
upstream region spanning from positions  1099 to +26
and containing 22 CpGs (Figure 5A). Figure 5B shows
that the CpG methylation pattern correlated with IL-6
expression (Figure 1). To evidence the relation between
the levels of methylation and gene expression, we clustered
the CpGs into ﬁve groups (I, II, III, IV and V) and we
summarized the methylation levels in four ranges, as
indicated in the ﬁgure. Group I was highly methylated
in all cell lines, while groups II and III presented diﬀerent
sites of methylation exclusively in the non-expressing cell
lines; remarkably, only position  426 was methylated
in all three non-expressing cell lines. Groups IV and V
were methylated in two non-expressing cell lines, PC
and PANC1, and in Paca44, the least IL-6-expressing
cell line. These results strongly suggest that the IL-6-
inducing activity of DAC in the non-expressing cell lines
depends on directly removing speciﬁc mCpGs located
between positions  666 and  426 and responsible for
transcriptional repression.
ChIP analysis of the IL-6 upstream region
To verify whether the diﬀerentially methylated IL-6
upstream region could bind MeCP2 and/or H3meK9, we
performed ChIP analysis. Figure 6A shows the pattern of
binding of RNA polymerase II, acetylated histone H4,
methylated histone H3 and MeCP2 on the upstream
region of IL-6 and  -ACTIN and on 16CEN, in an
IL-6-expressing (CFPAC1) and a non-expressing (PC)
cell line. While in CFPAC1 cells the pattern of binding
on IL-6 was similar to that of  -ACTIN, in PC cells, it
corresponded to that of 16CEN in control and TNF-a-
treated cells. Interestingly, following DAC or TNF-a/
DAC treatments, the pattern of binding on IL-6 became
similar to that of  -ACTIN also in PC cells. Results com-
parable to those shown for each representative cell line
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Figure 4. IL-6 expression following treatment with DAC or TSA. (A) Cells were treated with DAC (2.5mM) for 72h and/or TSA (300nM) for the
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Figure 6B shows the pattern of binding of RNA
polymerase II, acetylated histone H4, methylated histone
H3 and MeCP2 on the upstream region of IL-6 in all cell
lines following treatment with TNF-a and/or DAC.
H3meK9 and MeCP2 were present only in the three
non-expressing cell lines and disappeared after DAC treat-
ment, while H4Ac was present in all cell lines in the
absence or presence of treatments. To ﬁnely identify the
sequence that allows the recruitment of MeCP2/H3meK9
on the 50-ﬂanking region of IL-6, we performed ChIP
assays with a more systematic quantitative RT–PCR
analysis using six sets of primers located from  1141 to
+118. Figure 7 shows that the peak of MeCP2/H3meK9
binding was obtained with the primer set amplifying the
region located from  600 to  500. This ﬁnding indicates
that in IL-6 non-expressing cell lines MeCP2/H3meK9
binds at the 50-ﬂanking region of IL-6 around positions
 600/ 500. Together with the observation that DAC is
able to induce IL-6 mRNA (Figure 4) and prevent
MeCP2/H3meK9 binding (Figure 6B), these data
strongly suggest that IL-6 repression in pancreatic
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Figure 6. ChIP analysis. ChIP, qPCR and data analyses were performed as reported in ‘Materials and Methods’ section. DNA from each cell line in
each condition (control, TNF-a, DAC TNF-a/DAC) was immunoprecipitated in the absence or presence of the antibodies against PolII, H4Ac,
H3meK9, MeCP2 and a non-speciﬁc antibody (IgG). qPCR for each ChIP-DNA sample was performed for IL-6,  -ACTIN and 16CEN. Results are
reported as fold enrichment of immunoprecipitated DNA from each sample relative to the DNA immunoprecipitated with the non-speciﬁc antibody
(control), and were plotted in a scale in which the ﬁnal value of IgG was arbitrarily set to 1. (A) ChIP analysis of IL-6,  -ACTIN and 16CEN in two
representative cell lines, an IL-6-expressing (CFPAC1) and a non-expressing (PC) cell line. (B) ChIP analysis of IL-6 in all six cell lines performed
with IL6-5 primer pairs.
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MeCP2 and H3meK9 to the methylated CpG located
from positions  666 to  426 of IL-6.
DISCUSSION
In this study, we have investigated the molecular
mechanisms involved in IL-6 silencing in pancreatic
adenocarcinoma cell lines. Our results demonstrate that
TNF-a is able to induce IL-6 only in three out of six cell
lines examined, although all cell lines possess wild type
IL-6 and functional transcriptional machinery. Further-
more, we show that either in non-expressing or in IL-6-
expressing cell lines DAC, but not TSA, is able to induce
IL-6, indicating that DNA methylation, but not histone
deacetylation, plays an essential role in IL-6 silencing.
DAC might induce IL-6 by activating the expression of
genes that in turn activate IL-6 transcription. To verify
this hypothesis, we performed transfection experiments
with the pIL-6( 592) luciferase reporter plasmid
(Figure 4B). No signiﬁcant diﬀerence in luciferase
activity between untreated and DAC-treated cells was
observed. Since the transfected plasmid was completely
unmethylated, this result rules out the possibility that
DAC acts by an indirect mechanism. Consistent with
this hypothesis, we observed that neither DAC nor TSA
signiﬁcantly modiﬁed the binding activity of both NF-kB
and C/EBP, the major transcription factors in IL-6 acti-
vation (Figure 2).
Quantitative pyrosequencing analysis shows that the
CpG methylation status of the IL-6 upstream region in
the six cell lines examined correlates with IL-6 expression.
Methylation-dependent silencing of gene promoters gen-
erally depends on direct interfering with the binding
of transcription factors and/or speciﬁc recognition of
mCpGs by methyl-CpG-binding proteins that indirectly
repress transcription (22,23). To determine whether one
or both mechanisms were involved in IL-6 silencing of
pancreatic adenocarcinoma cell lines, we analysed the
DNA methylation proﬁle of the IL-6 upstream region
spanning from  1099 to +26. Positions  227,  212
and  162, which are close to the binding sites for tran-
scription factors necessary for IL-6 activation, were
methylated in a non-expressing cell line (Panc1) and in
the least expressing cell line (PaCa44). This ﬁnding
suggests that the reduced IL-6 induction by TNF-a in
PaCa44 cells (Figure 1) may depend on the interference
between transcription factors and methylated CpG, thus
supporting a direct mechanism of repression. On the other
hand, all IL-6 non-expressing cell lines showed mCpGs in
a region comprised from positions  666 to  426, which
does not contain transcription factor binding sites. This
result suggested the occurrence of an indirect methyl-
CpG-binding protein-mediated repression. Indeed, ChIP
analysis at the IL-6 upstream region revealed, around
positions  600/ 500, the presence of both MeCP2 and
H3meK9, which disappeared after DAC treatment, only
in the non-expressing cell lines. The presence of H3meK9
in non-expressing cells is consistent with its role in the
formation of a condensed and transcriptionally inactive
chromatin (26,30). Altogether, our results strongly
suggest that the major contribution to IL-6 silencing in
pancreatic adenocarcinoma cell lines is due to the
binding of MeCP2/H3meK9 to the methylated CpG
located from positions  666 to  426 of IL-6.
Klose et al. (31) have recently reported that MeCP2
requires (A/T) >4 sequences adjacent to the methyl-
CpGs for eﬃcient DNA binding. In particular, three to
eight/nine base pairs away from the methyl-CpG are nec-
essary and suﬃcient for high-aﬃnity MeCP2 binding. The
analysis of the IL-6 upstream region shows several (A/T)
>4 motifs (Figure 5A). Interestingly, only the sequences
immediately downstream to the methyl-CpG at positions
 666,  664 and  426 contain (A/T) >4 motifs corre-
sponding to the required feature. This observation
strongly supports the hypothesis that these methyl-
CpGs, especially the one located at position  426 that is
methylated in all three non-expressing cell lines, may act
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Figure 7. Systematic ChIP analysis of the IL-6 50-ﬂanking region. ChIP, qPCR and data analyses were performed as reported in ‘Materials and
Methods’ section. DNA from each cell line was immunoprecipitated in the absence or presence of the antibodies against MeCP2, H3meK9 and a
non-speciﬁc antibody (IgG). qPCR for each ChIP-DNA sample was performed with six primer pairs spanning from  1141 to +118 relative to IL-6
transcriptional start site (+1). Results are reported as fold enrichment of immunoprecipitated DNA from each sample relative to the DNA
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(A) ChIP analysis of IL-6 in the three non-expressing cell lines. (B) Location of the PCR products analysed in A on the IL-6 ﬂanking region.
6688 Nucleic Acids Research, 2009,Vol.37, No. 20as binding sites for MeCP2. Nevertheless, we cannot
rule out the possibility that MeCP2 binds unmethylated
DNA of the IL-6 upstream region through the connec-
tion to faraway DNA sequences via still unknown
mechanisms (32).
In the expressing cell lines, IL-6 induction by DAC,
which is lower than that observed in the non-expressing
cell lines, may depend on the demethylation of the IL-6
regions localized upstream to position  1001. We suppose
that in these cell lines DAC treatment is able to improve
the accessibility of the already transcriptionally active IL-6
promoter and to increase the constitutive IL-6 expression.
The methylation at any given site of the IL-6 region
downstream to position  666 appears to be incomplete,
as indicated by the diﬀerent percentage of the methylation
level (Figure 5B). This ﬁnding suggests allelic/cellular het-
erogeneity and is consistent with results already reported
by other authors (33,34).
In conclusion, we have presented the ﬁrst evidence of an
MeCP2/H3meK9-mediated epigenetic mechanism leading
to IL-6 silencing.
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